TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Rational Control of Fluid Balance in the Intensive Care Unit

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 18 or more~* Patients receiving endo-tracheal intubation and mechanical ventilation during their stay in the ICU~* Weight increase of at least 3 % during the stay. Baseline weight is regarded as the weight at the 24th hour after ICU admission~* FiO2 \< 60 %, PEEP \< 10cmH20~* No administration of catecholamines other than dobutamine at a dose of 10 microg.Kg-1.min-1~Exclusion Criteria:~* Pregnancy~* Patient with a moribund state at ICU arrival~* Acute brain injury (traumatic brain injury, subarachnoid hemorrhage, intra-cerebral bleeding, stroke, meningo-encephalitis, coma from medication origin)~* Chronic kidney disease defined as creatinin clearance \< 30mL.min-1 and/or with chronic dialysis~* Mandatory administration of diuretics (cardiogenic pulmonary oedema, LVEF \< 30 %)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Test Furosemide (Type: EXPERIMENTAL): We will test our furosemide algorithm in one arm
- Classical Strategy (Type: NO_INTERVENTION): It's a classical strategy without diuretics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LEO 29102 Cream in the Treatment of Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of atopic dermatitis defined according to Hanifin and Rajka~* IGA assessment scored as mild (2) to moderate (3) atopic dermatitis~* Treatment lesions located on the trunk and limbs~* Treatment lesions involving 3% to 10% of the total body surface area~* Patients of either gender between 18 years and 65 years of age~Exclusion Criteria:~* Systemic treatment with immunosuppressive drugs or corticosteroids within 6 weeks prior to randomisation~* Topical treatment with immunomodulators (pimecrolimus, tacrolimus) within 2 weeks prior to randomisation~* Topical treatment with corticosteroids from WHO groups II, III or IV within 1 week prior to randomisation~* Use of topical or systemic antibiotics within 2 weeks prior to randomisation~* PUVA or UVB therapy within 4 weeks prior to randomisation~* Clinical infection (viral, fungal or bacterial) on the treatment area~* Known or suspected severe renal insufficiency or severe hepatic disorders~* Patients with history of an immunocompromised disease (e.g., lymphoma, HIV, Wiskott-Aldrich Syndrome)~* Patients with concomitant serious disease (e.g., cancer) which might affect the AD treatment in this trial~* Females who are pregnant or are breast feeding~* Females intending to temporarily or permanently stop their hormonal contraceptive regime during and up to one month post study termination visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LEO 29102 0.03 mg/g cream (Type: EXPERIMENTAL): None
- LEO 29102 0.1 mg/g cream (Type: EXPERIMENTAL): None
- LEO 29102 0.3 mg/g cream (Type: EXPERIMENTAL): None
- LEO 29102 1.0 mg/g cream (Type: EXPERIMENTAL): None
- LEO 29102 2.5 mg/g cream (Type: EXPERIMENTAL): None
- LEO 29102 cream vehicle (Type: PLACEBO_COMPARATOR): None
- Elidel® cream (pimecrolimus) 10 mg/g (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venipuncture.~* Body mass index (BMI) between 18 and 30 kg/m2 (inclusive) and weight at least 50 kg but no more than 100 kg.~Exclusion Criteria:~* Clinically significant medical history including severe allergies or a history of mental disorders or any cardiac history, history or presence of gastrointestinal, hepatic, or renal disease.~* Abnormal heart rhythm including any abnormal arrhythmias, marked sinus arrhythmias, or junctional rhythms.~* Known or suspected history of drug abuse, current smokers or those who have smoked and/or used nicotine products within 3 months prior to enrollment.~* Excessive intake of caffeine-containing products

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): NKTR-118 25 mg (1x25 mg tablet + 5x placebo tablets)
- B (Type: EXPERIMENTAL): NKTR-118 150 mg (6x25 mg tablet)
- C (Type: PLACEBO_COMPARATOR): NKTR-118 placebo (6x placebo tablets)
- D (Type: ACTIVE_COMPARATOR): Moxifloxacin (1 x 400 mg tablet)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, at least 18 years of age at time of screening.~* Screening laboratory result indicating hepatitis C virus (HCV) genotype 1-6 (GT1-6) infection.~* Subject is a recipient of a cadaveric or living donor liver transplant which was a consequence of HCV infection at least 3 months prior to screening Or subject received a cadaveric or living donor kidney at least 3 months before screening.~* Subjects must be documented as non-cirrhotic.~* Subject is currently taking a stable immunosuppression regimen based on tacrolimus, sirolimus, everolimus, mycophenolate mofetil (MMF), mycophenolic acid, azathioprine, and/or cyclosporine.~Exclusion Criteria:~* Female subject who is pregnant, breastfeeding or is considering becoming pregnant during the study or for approximately 30 days after the last dose of study drug.~* Clinical history of fibrosing cholestatic hepatitis post-transplant.~* Re-transplantation of the liver or kidney.~* Steroid resistant rejection of the transplanted liver or kidney, or a history of rejection treated with high dose steroid within 3 months of screening.~* History of post-transplant complications related to hepatic or renal vasculature.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Glecaprevir/Pibrentasvir (Type: EXPERIMENTAL): Glecaprevir/pibrentasvir (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically / cytologically proven ADC-P~* Non-resectable disease~* 3-month expected survival~* No prior radiotherapy or chemotherapy~* Age \>= 18 years old~* Performance status \< 4 (WHO)~* Adequate blood biological parameters~Exclusion Criteria:~* Abnormal initial fibroscopy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)~  * Stage IIIA or IIIB disease~* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion \> 20 mm by conventional techniques or \> 10 mm by spiral CT scan~* No clinically significant malignant pleural or pericardial effusion (i.e., stage IIIB wet disease)~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Absolute neutrophil count \> 1,500/mm³~* Platelet count \> 100,000/mm³~* Hemoglobin ≥ 8.0 g/dL~* Bilirubin normal~* Alkaline phosphatase (AP), AST, and ALT meeting 1 of the following criteria:~  * AP normal AND AST or ALT ≤ 5 times upper limit of normal (ULN)~ * AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN~ * AP ≤ 5 times ULN AND AST or ALT normal~* Creatinine \< 2.0 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for ≥ 3 months after completion of study treatment~* No New York Heart Association class III-IV heart disease~* No history of serious cardiac disease not adequately controlled~* No documented myocardial infarction within the past 6 months~* No congestive heart failure~* No unstable angina~* No clinically significant arrhythmia~* No history of severe hypersensitivity reaction to drugs formulated with polysorbate 80~* No peripheral neuropathy \> grade 1~* No other malignancy within the past 5 years other than skin cancer~PRIOR CONCURRENT THERAPY:~* More than 3 weeks since prior major surgery~* No prior systemic chemotherapy, thoracic radiotherapy, or surgical resection for NSCLC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy boys and girls aged 10 to 12 years~2. Those who received primary immunization (5 doses of diphtheria and tetanus vaccination until the age of 6)~3. Voluntary written consent of the subject and the legally acceptable representative(LAR) to participate in this clinical study~Exclusion Criteria:~1. 2 weeks have not passed since recovery from an acute disease~2. Temporary thrombocytopenia or neurological complications due to diphtheria or tetanus vaccination~3. History of a severe allergy to any component of the investigational product~4. History of a severe adverse event due to administration of diphtheria, tetanus, or diphtheria tetanus combined vaccine~5. Administration of tetanus, diphtheria, or diphtheria tetanus combined vaccine within 5 years~6. Unable to verify diphtheria and tetanus vaccination completed until the age of 6~7. History of infection with diphtheria or tetanus (if clinically, serologically or microbiologically confirmed)~8. Current chronic disease that impedes implementation or completion of the clinical study~9. Scheduled surgery during the study period~10. Acute fever with a tympanic temperature exceeding 38.0ºC within 72 hours before administration of the investigational vaccine~11. Administration of other vaccines within 28 days before screening~12. Use of immunosuppressants or immune modifying drugs within 3 months before screening~13. Those who have received immunoglobulin therapies or blood derived products within 3 months before screening, or are expected to receive them during the study period~14. Use of antipyretics/analgesics/nonsteroidal anti inflammatory drugs within 4 hours before administration of the investigational vaccine~15. Participation in other clinical studies within 28 days before screening~16. Those who were determined by the investigator to be ineligible for other reasons

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- BR-TD-1001 (Type: EXPERIMENTAL): Randomized subjects were assigned to receive a single dose of BR-TD-1001
- Td-pur inj (Type: ACTIVE_COMPARATOR): Randomized subjects were assigned to receive a single dose of Td-pur inj

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetic macular edema with center involvement in at least one eye~* Type 1 or type 2 diabetes mellitus diagnosed 2 years prior to screening~* Laser photocoagulation in the study eye can be withheld for at least 3 months after randomization~Exclusion Criteria:~* Patients with uncontrolled systemic or ocular diseases~* Have any history of any intraocular surgery in the study eye within the past 6 months preceding screening~* Conditions that require chronic concomitant therapy with systemic or topical ocular corticosteroids~Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab 0.3 mg (Type: EXPERIMENTAL): Participants received monthly intravitreal injections with 0.3 mg ranibizumab (6 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 0.6 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
- Ranibizumab 0.5 mg (Type: EXPERIMENTAL): Participants received monthly intravitreal injections with 0.5 mg ranibizumab (10 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 1.0 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
- Sham injection (Type: SHAM_COMPARATOR): Participants in the control group received 12 monthly sham intravitreal injections. The evaluation was performed using the same criteria for dose doubling as in active treatment groups. The injection was a mimicked by an empty syringe without a needle. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimization of Vonoprazan--amoxicillin Dual Therapy for Eradicating Helicobacter Pyloriinfection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-70, regardless of gender; HP positive in 13C/14C breath test or pathological test; HP eradication has never been performed in the past; Based on the consensus of helicobacter pylori in 2017, it conforms to the HP eradication guideline; The patient voluntarily signed the informed consent.~Exclusion Criteria:~* History of drug allergy in this study; Liver and kidney dysfunction; Cardiopulmonary insufficiency; History of malignant tumor; Taking clopidogrel, warfarin and other drugs simultaneously may affect CYP2C19 metabolism; Pregnant or lactating women; Patients with severe mental illness; Those planning pregnancy; Previous upper gastrointestinal surgery history; Participated in any other clinical investigator in the last 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- H-VA-dual-10 (Type: EXPERIMENTAL): 10 days(vonoprazan fumarate tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 750mg/ time, 4 times/day, oral)
- L-VA-dual-10 (Type: EXPERIMENTAL): 10 days(vonoprazan fumarate tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 1000mg/ time, 2 times/day, oral)
- H-VA-dual-14 (Type: ACTIVE_COMPARATOR): 14 days(vonoprazan fumarate tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 750mg/ time, 4 times/day, oral)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Carotid atherosclerosis~* Femoral atherosclerosis~* Cardiovascular risk~Exclusion Criteria:~* Heart failure~* Renal disease~* Liver disease~* Life-threatening diseases

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of metastatic breast cancer~* Previous treatment with anthracyclines and taxanes~* Patients who will start Eribulin or who have already received only the first dose (cycle 1, day 1) of Eribulin according to the approved indication~* Ability to comply with sample collection~* Patient has signed the study Informed Consent Form (ICF) and the specific Pharmacogenetic ICF.~* Absence of any contraindication to treatment~Exclusion Criteria:~* Previous treatment with Eribulin in a previous line of treatment~* Previous treatment with Eribulin off label

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm with Eribulin mesylate (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
PROTOCOL INCLUSION CRITERIA~* Patients must be 18 years of age or older.~* Males and females. If women of childbearing potential (i.e., not surgically sterilized or post-menopausal greater than one year) the patient must be using effective birth control.~* Diagnosis of AA amyloidosis demonstrated by positive biopsy (Congo red staining) and immunohistochemistry or immunoelectron microscopy at screening visit. Tissue from previous biopsy can be used for confirmation of diagnosis, if available.~* Persistent proteinuria defined as urinary protein excretion ? 1g/24h in two distinct 24-h urine collections at least 1 week apart within 3 months prior to study entry (baseline, Month 0 visit) without evidence of urinary tract infection or overt heart failure (NYHA class III or more); OR creatinine clearance ? 60 mL/min in two distinct measures at least 1 week apart within 3 months prior to study entry (baseline, Month 0 visit).~* Creatinine clearance ? 20 mL/min AND serum creatinine ? 3 mg/dl within 3 months prior to study entry (baseline, Month 0 visit).~* Written informed consent.~PROTOCOL EXCLUSION CRITERIA~* Evidence or suspicion of renal or renovascular diseases other than renal AA amyloidosis.~* Presence of diabetes mellitus (Type I and II).~* Evidence of a cause of potentially reversible reduced renal function, such as accelerated hypertension or drug nephrotoxicity.~* AST, ALT, or ALP \> 5 times the upper limit of normal, or total bilirubin 50% above upper limits of normal.~* Presence of any other clinically significant diseases that could interfere with the interpretation of study results or compromise patient safety or any conditions that could reduce life expectancy to less than two years.~* Use of an investigational drug within thirty days prior to the screening visit.~* Active alcohol and/or drug abuse.~* Initiation of or any changes in ACE inhibitor therapy within 3 months prior to the screening visit.~* Initiation of or any changes in cytotoxic agents/colchicine therapy within 3 months prior to the screening visit.~* Inability to provide legal consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete